NCT04985357 2024-11-25Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsTravera IncWithdrawn
NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn
NCT02567396 2017-04-24Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionNational Cancer Institute (NCI)Phase 1 Withdrawn